Brief: Vicore Confirms IPF Development Program On Track, Provides Updates
Jan 2 (Reuters) - Vicore Pharma Holding AB VICOR.ST :
* VICORE CONFIRMS IPF DEVELOPMENT PROGRAM ON TRACK AND
PROVIDES
EARLY-STAGE PIPELINE UPDATES
* TOPLINE RESULTS FROM ALMEETM PIVOTAL STUDY COMPANION
EXPECTED TO
BE ANNOUNCED THIS MONTH
* CONTINUES TO FOCUS ON DEVELOPMENT OF C21 FOR IDIOPATHIC
PULMONARY FIBROSIS (IPF)
Source text for Eikon: ID:nMFN8cnf1g
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2